NOT AN OFFER TO INVEST. RED HERRING DISCLOSURE AVAILABLE ON REQUEST. PROFESSIONAL INVESTORS ONLY.

About Peter A. Jensen

This author has not yet filled in any details.
So far Peter A. Jensen has created 96 blog entries.

Meet the Press. As the Covid national emergency ends, what was its overall impact? 1.1 million Americans died. U.S. economy net loss $14 trillion.

Meet the Press FOR EDUCATIONAL PURPOSES As the Covid [...]

By |2023-05-22T05:26:20+00:00May 22, 2023|Blog Posts|Comments Off on Meet the Press. As the Covid national emergency ends, what was its overall impact? 1.1 million Americans died. U.S. economy net loss $14 trillion.
Read More

INVESTIGATIVE REPORT. Lessons from the COVID War. Philip Zelikow: “We are as vulnerable to a pandemic today as we were at the beginning of 2020.”

Lessons from the Covid War: An Investigative Report [...]

By |2023-05-01T19:54:03+00:00May 1, 2023|Blog Posts|Comments Off on INVESTIGATIVE REPORT. Lessons from the COVID War. Philip Zelikow: “We are as vulnerable to a pandemic today as we were at the beginning of 2020.”
Read More

THE WASHINGTON POST. White House launching $5 billion program to speed coronavirus vaccines. ‘Project Next Gen’ would succeed ‘Operation Warp Speed’ with a mission to develop next-generation vaccines and therapies. 10 APRIL 2023

FOR EDUCATIONAL PURPOSES THE WASHINGTON [...]

By |2023-04-11T02:33:21+00:00April 11, 2023|Blog Posts|Comments Off on THE WASHINGTON POST. White House launching $5 billion program to speed coronavirus vaccines. ‘Project Next Gen’ would succeed ‘Operation Warp Speed’ with a mission to develop next-generation vaccines and therapies. 10 APRIL 2023
Read More

THE ECONOMIST. The pandemic’s true death toll. Between 17,500,000 and 29,800,000 Lives Lost to SARS-CoV-2. Updated 31 March 2023.

Estimated DEATHS from COVID: Between 17,500,000 and 29,800,000 Lives Lost [...]

By |2023-03-31T08:00:36+00:00March 31, 2023|Blog Posts|Comments Off on THE ECONOMIST. The pandemic’s true death toll. Between 17,500,000 and 29,800,000 Lives Lost to SARS-CoV-2. Updated 31 March 2023.
Read More

BOOK. The AI Revolution in Medicine: GPT-4 and Beyond. by Peter Lee, Carey Goldberg, Isaac Kohane. May 3, 2023. AMAZON.

BOOK. The AI Revolution in Medicine: GPT-4 and Beyond. by [...]

By |2023-03-28T06:03:17+00:00March 28, 2023|Blog Posts|Comments Off on BOOK. The AI Revolution in Medicine: GPT-4 and Beyond. by Peter Lee, Carey Goldberg, Isaac Kohane. May 3, 2023. AMAZON.
Read More

Progress, Potential, and Possibilities. Dr. John-Arne Røttingen, MD, PhD – Ambassador for Global Health, Ministry of Foreign Affairs, Norway. 27 Mar 2023

Global Health Diplomacy, Science And Innovation - [...]

By |2023-03-28T03:07:09+00:00March 28, 2023|Blog Posts|Comments Off on Progress, Potential, and Possibilities. Dr. John-Arne Røttingen, MD, PhD – Ambassador for Global Health, Ministry of Foreign Affairs, Norway. 27 Mar 2023
Read More

NATURE MEDICINE. EDITORIAL. 14 March 2023. Will ChatGPT transform healthcare?

Will ChatGPT transform healthcare? "Within a constructive and alert regulatory [...]

By |2023-03-19T16:42:56+00:00March 19, 2023|Blog Posts|Comments Off on NATURE MEDICINE. EDITORIAL. 14 March 2023. Will ChatGPT transform healthcare?
Read More

SCIENCE. RESEARCH ARTICLE. PROTEIN STRUCTURE PREDICTION BY AI LLM. Evolutionary-scale prediction of atomic-level protein structure with a language model

SCIENCE. RESEARCH ARTICLE. STRUCTURE PREDICTION.Evolutionary-scale prediction of atomic-level protein structure [...]

By |2023-03-19T16:20:40+00:00March 19, 2023|Blog Posts|Comments Off on SCIENCE. RESEARCH ARTICLE. PROTEIN STRUCTURE PREDICTION BY AI LLM. Evolutionary-scale prediction of atomic-level protein structure with a language model
Read More

DISEASE-X SIMULATION. What if the Next Pandemic Happened Tomorrow? Opinion. The New York Times

Disease-X Simulation. Opinion. What if the Next Pandemic Happened [...]

By |2023-03-13T07:05:05+00:00March 13, 2023|Blog Posts|Comments Off on DISEASE-X SIMULATION. What if the Next Pandemic Happened Tomorrow? Opinion. The New York Times
Read More

HEALTH. Covid backlash hobbles public health and future pandemic response. The Washington Post.

HEALTH Covid backlash hobbles public health and future pandemic response [...]

By |2023-03-08T21:30:47+00:00March 8, 2023|Blog Posts|Comments Off on HEALTH. Covid backlash hobbles public health and future pandemic response. The Washington Post.
Read More
Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.2023-02-03T11:00:00+00:00

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax Abstract2022-08-31T11:50:39+00:00

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.

Copyright 2021 | Normax Biomed Limited | First Floor, Penrose 1, Penrose Dock, Cork, Ireland | T23 KW81 | Company Number 669518

Go to Top